Compare IMMP & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | DENN |
|---|---|---|
| Founded | 1987 | 1953 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 319.8M |
| IPO Year | N/A | 1989 |
| Metric | IMMP | DENN |
|---|---|---|
| Price | $3.15 | $6.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.45 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 02-22-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | $3,306,742.00 | ★ $457,212,000.00 |
| Revenue This Year | $292.48 | $6.56 |
| Revenue Next Year | N/A | $1.56 |
| P/E Ratio | ★ N/A | $31.66 |
| Revenue Growth | ★ 31.28 | 0.93 |
| 52 Week Low | $1.32 | $2.85 |
| 52 Week High | $3.53 | $7.66 |
| Indicator | IMMP | DENN |
|---|---|---|
| Relative Strength Index (RSI) | 78.17 | 66.18 |
| Support Level | $2.52 | $6.13 |
| Resistance Level | $2.86 | $6.24 |
| Average True Range (ATR) | 0.32 | 0.02 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 75.50 | 64.29 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.